Xeris Biopharma Holdings, Inc.
XERS evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for XERS—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · XERS
Xeris Biopharma Holdings, Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for endocrine and metabolic disorders, with marketed products Recorlev, Gvoke, and Keveyis.
Key risk: High accumulated deficit
BioSniper Score
Based on 6 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 4 pipeline candidates · 1 clinical trial · 1 catalyst for Xeris Biopharma Holdings, Inc..
Xeris Biopharma Holdings, Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for endocrine and metabolic disorders, with marketed products Recorlev, Gvoke, and Keveyis.
- Recorlev net revenue was $139.3 million in 2025, an increase of approximately 117% year-over-year [sec · filed 2026-04-23].
- Gvoke net revenue was $94.1 million in 2025, an increase of approximately 14% year-over-year [sec · filed 2026-04-23].
- Cash and equivalents were $125.8M as of 2026-06-30 [sec].
- Total revenue was $92.1M for the quarter ended 2026-06-30 [sec].
- Accumulated deficit was $700.2 million as of June 30, 2026 [sec_mda · as of 2026-08-06].
What works
- Recorlev revenue grew 117% in 2025, driven by increased patient demand [sec · filed 2026-04-23].
- Gvoke revenue grew 14% in 2025, supported by higher patient demand and favorable net pricing [sec · filed 2026-04-23].
- Management believes cash resources are sufficient to sustain operations for at least the next twelve months as of June 30, 2026 [sec_mda · as of 2026-08-06].
What to weigh
- The company has an accumulated deficit of $700.2 million as of June 30, 2026 [sec_mda · as of 2026-08-06].
- Net loss was $31.1M for the quarter ended 2026-06-30 [sec].
- Total debt was $316.4M as of 2026-06-30 [sec].
- Keveyis net revenue decreased approximately 4% in 2025 due to unfavorable net pricing [sec · filed 2026-04-23].
From the filings
Quoted directly from source documents.
Recorlev revenue growth in 2025
“Recorlev ® net revenue was $139.3 million - an increase of approximately 117% compared to the year ended December 31, 2024.”
SEC filings · April 23, 2026
Accumulated deficit as of June 30, 2026
“We have an accumulated deficit of $700.2 million at June 30, 2026.”
SEC MD&A · August 6, 2026
Cash sufficient for next twelve months
“Based on our current operating plans and existing working capital at June 30, 2026, we believe that our cash resources are sufficient to sustain operations and capital expenditure requirements for at least the next twelve months.”
SEC MD&A · August 6, 2026
Catalyst timeline
- 2040-03-02 · Patent_Expiry · RECORLEV — Patent/exclusivity expiry for Recorlev; potential generic competition thereafter.
Risks & what to watch (4)›
Key risks
- High accumulated deficit — Accumulated deficit of $700.2M as of June 30, 2026 [sec_mda · as of 2026-08-06].
- Significant debt burden — Total debt of $316.4M as of 2026-06-30 [sec].
- Continued net losses — Net loss of $31.1M for quarter ended 2026-06-30 [sec].
- Keveyis revenue decline — Keveyis net revenue decreased 4% in 2025 due to unfavorable net pricing [sec · filed 2026-04-23].
What to watch
- Recorlev and Gvoke revenue growth trajectory in 2026 [sec · filed 2026-04-23].
- Ability to reduce net losses and achieve profitability [sec_mda · as of 2026-08-06].
- Management of debt and cash runway [sec_mda · as of 2026-08-06].
- Pipeline progress, particularly XP-8121 development [sec · filed 2026-04-23].
Sources: SEC filings · SEC MD&A · Generated August 23, 2026 · How we verify sources →
Run Xeris Biopharma Holdings, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Xeris Biopharma Holdings, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 6 of 6 signals · derived from public data
Profitable (positive operating cash flow)
OCF $8M · Net income -$31M · Debt/OCF 5.8×
Lead: Approved
4 candidates
1 upcoming, next in ~4933d
0 buys · 15 sells (180d)
Catalysts
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
233
Total value held
$549.9M
| Holder | Shares | Value |
|---|---|---|
| blackrock, inc. | 12,945,785 | $75.1M |
| d. e. shaw & co., inc. | 7,788,811 | $45.2M |
| vanguard capital management llc | 6,980,882 | $40.5M |
| state street corp | 4,658,174 | $27.0M |
| geode capital management, llc | 4,290,629 | $24.9M |
| vanguard portfolio management llc | 2,665,608 | $15.5M |
| morgan stanley | 2,572,654 | $14.9M |
| millennium management llc | 2,265,974 | $13.1M |
| wellington management group llp | 2,171,354 | $12.6M |
| two sigma investments, lp | 1,924,202 | $11.2M |
Showing top 10 of 233 institutional holders of Xeris Biopharma Holdings, Inc.. Open the full 13F history after sign-in.
Short Interest
as of May 22, 2026- % of float
- 9.5%
- Days to cover
- 11.1
- Shares short
- 15,894,656
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
XERS short interestGovernance
Frequently asked questions
What is the AI investment thesis for Xeris Biopharma Holdings, Inc.?
Xeris Biopharma Holdings, Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for endocrine and metabolic disorders, with marketed products Recorlev, Gvoke, and Keveyis.
What is Xeris Biopharma Holdings, Inc.'s lead drug candidate?
Xeris Biopharma Holdings, Inc.'s most advanced tracked candidate is Gvoke (Approved) for Treatment of severe hypoglycemia; indicated for use in pediatric and adult patients with diabetes age two years and above.
What is Xeris Biopharma Holdings, Inc.'s next catalyst?
Xeris Biopharma Holdings, Inc.'s next tracked catalyst is a Patent_Expiry event — "Patent/Exclusivity Expiry: RECORLEV" — expected March 2, 2040.
Who is the CEO of Xeris Biopharma Holdings, Inc.?
Mr. John P. Shannon is the chief executive officer of Xeris Biopharma Holdings, Inc. (XERS).
Where is Xeris Biopharma Holdings, Inc. headquartered?
Xeris Biopharma Holdings, Inc. (XERS) is headquartered in Chicago, IL, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.